The customer contacted the siemens customer care center (ccc) to report a falsely elevated, atellica im ca 15-3 (ca 15-3) patient result.Siemens has completed the investigation.Based on the available information and a review of the complaint handling database, there were no other similar atellica ca15-3, reagent lot 188 complaints identified of other customers indicating this is a customer site specific issue.The repeated/corrected results were performed on atellica im system (b)(4).Siemens has reviewed the customer calibrations and quality control (qc) during the time frame of the incident.The reagent readypack in use at the time of the discordant ca 15-3 result required recalibration of the reagent readypack in use due to failing qc as oppose to the initial reagent lot calibration.Reagent lot calibration is valid for reagent readypacks of the same reagent lot in use until the calibration interval expires, however the reagent readypack required a calibration and manual customer acceptance to rectify qc out of range.This indicates a potentially compromised reagent readypack that was either not well mixed and/or exposed to light during shipping/handling/storage.The qc results on reagent readypacks currently in use by the customer are now within acceptable ranges.A systemic product performance issue was not observed.The customer is operational.The instruction for use (ifu) states in the interpretation of results section: "results of this assay should always be interpreted in conjunction with patient's medical history, clinical presentation and other findings." the instruction for use (ifu) states in the limitation warning and note section: "do not use the atellica im ca 15-3 assay as a screening test or for diagnosis.Normal levels of ca 15[- do not always preclude the presence of disease.Do not interpret levels of ca 15-3 as absolute evidence of the presence or the absence of malignant disease.Before treatment, patients with confirmed breast carcinoma frequently have levels of ca 15-3 within the range observed in healthy individuals.Additionally, elevated levels of ca 15-3 can be observed in patients with nonmalignant diseases.Measurements of ca 15-3 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation." the assay is performing within specifications.No further evaluation of the device is required.
|
A falsely elevated, atellica im ca 15-3 (ca 15-3) result was obtained on a patient sample and considered discordant compared to a lower result observed when the same sample was re-tested after assay recalibration using a new reagent readypack.The customer's quality control (qc) results were observed to be out of range at the time of the incident and repeat testing was performed after acceptable qc results were obtained.The lower repeat result was reported as the corrected result to the physician(s).There are no known reports that treatment was altered or prescribed or adverse health consequences due to the discordant, atellica im ca 15-3 (ca 15-3) result.
|